Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Insulin Sensitizer Has Anti-inflammatory Effect in Diabetics

17.06.2002


Study has implications for lowering heart-disease risk in Type 2 diabetes patients



A drug used widely as an insulin sensitizer appears also to have a significant anti-inflammatory effect in diabetics, a property that could make it useful in helping to prevent heart disease in these patients, a study by endocrinologists at the University at Buffalo has found.

Results of the research, involving the drug rosiglitazone, were presented here today (June 15, 2002) at the annual meeting of the American Diabetes Association. Rosiglitazone is sold under the brand name Avandia(r).


UB endocrinologists, led by Paresh Dandona, M.D., professor of medicine and head of the Division of Endocrinology in the UB School of Medicine and Biomedical Sciences, have been studying the anti-inflammatory properties of insulin and insulin sensitizers and their potential use in treatment and prevention of atherosclerosis, one of the leading causes of heart attacks.

Atherosclerosis, or hardening of the arteries, begins as an inflammation of the blood-vessel wall. Persons with diabetes are at increased risk of developing atherosclerosis and heart disease. Dandona’s lab has shown in research with a small group of obese non-diabetic volunteers that rosiglitazone decreased the levels of oxygen free radicals which can begin the inflammation cascade by injuring blood-vessel linings. The drug also decreased the levels of several blood markers of inflammation.

The current study involved 11 obese patients with Type 2 diabetes. In this disease, also referred to as adult-onset diabetes, the body produces adequate amounts of insulin, but cells don’t respond to its action. Rosiglitazone is prescribed to break down this resistance to insulin.

Researchers collected blood samples from the diabetic volunteers and started them on a six-week course of daily rosiglitazone. They repeated the blood sampling four times during the six weeks of treatment and again at 12 weeks, and analyzed the samples for concentration of three inflammatory markers and for the presence of oxygen free radicals.

Results showed that the drug exerted a "profound" suppressive effect on free radicals and on other mediators of inflammation in the blood.

"The ability to reduce inflammation is crucial for preventing atherosclerosis and cardiovascular disease, " said Dandona. "Previous data demonstrated rosiglitazone’s effectiveness in reducing key markers of cardiovascular disease in patients at risk for diabetes. This study in people with diabetes further underscores rosiglitazone’s potential to have a cardio-protective effect."

Analysis of blood samples showed that at six weeks, free radical generation had dropped about 34 percent from baseline. Concentration of the inflammatory markers plasma monocyte chemoattractant protein-1 (MCP-1) and C-reactive protein (CRP) fell by 25 percent and 30 percent, respectively, at six weeks. At 12 weeks inflammatory markers had returned to baseline.

Rosiglitazone also improved vascular reactivity - the ability of vessels to expand and contract in response to changes in blood flow -- which is crucial for maintaining healthy blood pressure and blood flow to vital organs.

Also involved in the study, all from UB’s department of Medicine, were Priya Mohanty, M.D.; Ahmad Alijada, Ph.D.; Husam Ghanim; Deborah Hofmeyer; Devjit Tripathy, M.D., and Sandeep Dhindsa, M.D.

The study was funded by GlaxoSmithKline, manufacturer of Avandia.

Lois Baker | EurekAlert

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>